CAPR (Capricor Therapeutics Inc.) Net earnings per share (EPS TTM)

Capricor (CAPR) - corporate logo

Capricor Therapeutics (CAPR) operates in a defensive sector where demand for healthcare remains independent of global crises. Capricor Therapeutics (CAPR) is implementing an innovative cellular platform to combat cardiomyopathy, expanding its business through a partnership with Nippon Shinyaku. This price chart on GURU.Markets illustrates that the TTM EPS is -46.90. However, the project's success depends on competing with the genetic engineering developments of other market players.

Capricor - CAPR Earnings per share for the last twelve months (period 02/11/2024 - 11/16/2026)

CAPR (Capricor): analytical breakdowns and indicator data

Fundamental company valuation:CAPR Capricor Therapeutics
Flagship merchandise of Capricor Therapeutics Inc.

Strategic alliances of Capricor Therapeutics (CAPR) in neurological pharma are accelerating clinical trials and M&A processes. The annual growth of basic net income per share (TTM) reflects profit dynamics over four quarters relative to the previous year. This chart allows for the identification of overheating or margin compression due to operating expenses. A stable trend for this indicator confirms the effectiveness of the business model and the resilience of the issuer's market quotes.